Key Questions RAS Can Help You Answer

  • What is the current solid tumor clinical development landscape?

  • What are the key market impacting events?

  • What´s the strategy of major Oncology players?

  • What´s the positioning and strategy for a molecule of interest?

  • What are the upcoming innovation waves? What are the opportunities created by them?

  • What´s the current state-of-the-art in cancer biomarkers?

  • How to keep pace with the regulatory policies & payer positions across geographies?

  • What drug candidates/ companies are suitable for partnering or in-licensing for oncology therapeutics?

Featured Insights

August 16, 2018 / infographics, Oncology

Evolution In EGFRM+ Lung Cancer

Interest in the EGFR Lung cancer space initially started with the isolation of Epidermal growth factor (EGF) gene by Stanley Cohen in 1962 as a protein extracted from the mouse submaxillary gland that accelerated incisor eruption. Therefore, it was originally termed ‘tooth-lid factor’, but was later renamed EGF because it stimulated the proliferation of epithelial cells. Since then substantial progress has been made against lung cancer over the last two decades. Research has also powered the emergence of new targeted treatments which are helping patients live a longer and higher quality life after a lung cancer diagnosis. This infographic allows the reader to dwell deeper and look closely into the history of discovery, evolution and advancements pertaining to EGFR lung cancer space.
Read More
June 4, 2018 / ASCO18, infographics, Oncology

Major Milestones in Cancer Research

Research and development within the cancer field is continuously evolving and progressing. This infographic highlights the biggest milestones within the field of cancer research spanning 170 years —from the advent of general anesthesia opening the door for cancer surgery in the mid-1800s to the first gene therapy for cancer approved by the Food and Drug Administration in 2017.
Read More
May 25, 2018 / Featured Insights, Oncology

Nanotechnology in Drug Discovery and Design

This presentation takes the reader on an exciting journey, about the Science beneath the development of Oncology Nano Drug delivery systems. How the tumor mico and macro environments throws conspicuous challenges to the nanotech field? Furthermore, the presentation also gives a sneak view of Nanotherapeutics clinical landscape across development strategies and tumors.
Read More
July 18, 2017 / Biosimilars, Featured Insights, Oncology

Oncology Biosimilar Competitive Dynamics

This paper attempts to present situation analysis of the current marketplace of Oncology biosimilars specially with respect to the industry’s micro-environment. The research and analysis herein, intends to identify positive forces and interactions that are shaping an attractive biosimilar industry in both US and EU markets.
Read More

Read Our Blogs

May 30, 2017

AbbVie @ASCO 2017

AbbVie will present a total of 23 abstracts across several tumor types including brain cancer, hematologic malignancies, breast cancer, lung cancer and other solid tumors. Researchers will present efficacy and safety data on depatuxizumab mafodotin, an antibody-drug conjugate (ADC) being studied for the treatment of adults with amplified EGFR newly […]
May 28, 2017

Liquid Biopsies in Cancer: Opportunities and Challenges

Liquid Biopsy is a term given to a minimally invasive method of analyzing Tumor cell DNA circulating in the blood. This is a useful and very promising approach and opens new vistas compared to the Biochemical Biomarkers and Tissue Biopsies dependent monitoring of cancer. However, it throws its own challenges […]
May 28, 2017

CRC Abstracts – RAS Viewpoint

At ASCO 2017, the steadily increasing competitive intensity between Lonsurf (TAS-102, Taiho) and Stivarga (regorafenib, Bayer) will be on display . In addition, the I/O agents are reading out both as monotherapy in specific (dMMR/MSI-H) patient segments, as well as in combinations with other cytotoxic and targeted agents in broader patient […]
May 26, 2017

Prostate Cancer Abstracts – RAS Viewpoint

ASCO 2017 is primarily setting the stage for future as it relates to Prostate Cancer – a large number of presentations are focused on early stage data from new compounds and/or combinations of existing. The truly practice impacting trials such as IMbassador250, ARASENS, PROfound and TRITON3 will be touched upon […]
May 23, 2017

Biomarkers in Colorectal Cancer

Colorectal Cancer Diagnostics and monitoring CRC diagnostics and monitoring follows two pronged strategy Diagnostic tools such as Colonoscopy: Specific, Can Remove Polyps and Take Biopsies. Adverse: Can cause perforation, Can miss small adenomas Flexible sigmoidoscopy: Specific, Can Remove Polyps and Take Biopsies. Adverse: Reduced risk of perforation Double-contrast barium enema: […]
May 22, 2017

Future of Cancer Care 2030 – RAS Viewpoint

There are four areas of innovation that are noticeable both in isolation and how they feed into each other for a transformation in cancer care “Big data” and Bioinformatics – rapidly developing data management systems and analytics e.g. NGS that will enable us to collect, analyze and learn from vast amounts […]

What would you like to know?